Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases Positive Preclinical Data from Hemophilia Program

Premium

Alnylam Pharmaceuticals this week released preclinical data showing that ALN-AT3, its investigational treatment for hemophilia and other bleeding disorders, can normalize thrombin generation and improve hemostasis in hemophilia mice and fully correct thrombin generation in a non-human primate hemophilia inhibitor model.

The findings were presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis in Amsterdam.

According to the company, a single subcutaneous dose of ALN-AT3 that resulted in plasma antithrombin reduction of 90 percent led to normalization of thrombin generation in hemophilia B mice. I a microvessel laser injury model, both hemophilia A and hemophilia B mice treated with a single subcutaneous dose of ALN-AT3 demonstrated “marked improvements” in hemostatic plug formation compared to untreated animals.

Meanwhile, in wild-type non-human primates, repeat dosing with ALN-AT3 resulted in “potent, titratable, and reversible silencing of plasma antithrombin, the company said.

Weekly subcutaneous doses of 0.50 mg/kg resulted in 90 percent antithrombin knockdown, and an ED50 knockdown was achieved at a dose as low as 0.125 mg/kg, Alnylam added.

“Dosing was continued for over five months with consistent pharmacologic effects, including no evidence of tachyphylaxis or any neutralizing immune response associated with prolonged exposure to ALN-AT3.”

In a hemophila inhibitor model, in which a hemophilia A phenotype is induced via administration of a polyclonal anti-factor VIII antibody, six weekly doses of ALN-AT3 at 0.25 or 0.50 mg/kg resulted in an “expected” level of antithrombin knockdown, as well as a statistically significant dose-dependent increase in thrombin generation, restoring this hemostatic parameter back to normal.

“These results demonstrate that ALN-AT3 can normalize thrombin generation in the absence of functional levels of factor VIII and/or in the presence of anti-factor VIII antibodies in a large animal model, providing key proof of concept for the program,” Alnylam said.

ALN-AT3 is slated to move into phase I testing later this year.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.